Testing Visugromab Added to Nivolumab for Metastatic Non-Small Cell Lung Cancer After Earlier Treatment
Tests visugromab combined with nivolumab in adults whose metastatic lung cancer returned after earlier treatment.
Plain-language title generated from the registry record
Registry title: Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Key facts
- Where
- Bielefeld, Essen, Esslingen am Neckar, Gauting, Grosshansdorf, Heidelberg, Moers, and Wuerzburg, GermanySee the 8 sites
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with stage IV non-squamous lung cancer whose cancer grew during first-line treatment that included a checkpoint inhibitor.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Disease stage
- Stage IV non-squamous non-small cell lung cancer, confirmed under the microscope, with measurable disease. Life expectancy of at least 3 months and ECOG performance status of 1 or lower.
- Earlier treatment
- Must have had exactly one earlier treatment line for metastatic disease that included an anti PD (L)1 checkpoint inhibitor, for at least 12 weeks with no progression in that time. The cancer must have grown while still on the checkpoint inhibitor. Stopping it for side effects or any reason other than progression or relapse does not allow joining.
- Biomarker or test result
- No actionable mutations (for example EGFR, ALK) that call for a targeted drug.
Main reasons for not taking part
- More than one earlier treatment line for advanced or metastatic lung cancer
- Another earlier cancer that needed treatment
- Active cancer in the central nervous system, for example symptomatic metastases or carcinomatous meningitis
- Active autoimmune disease that needed systemic treatment in the past 3 months
- Interstitial lung disease, or pneumonitis (not caused by infection) that needed systemic steroids, or current pneumonitis
Read by machine on 9 November 2026.
Where in Germany
- Evangelisches Klinikum Bethel gGmbHBielefeld, GermanyTaking people
- KEM I Evang. Kliniken Essen-Mitte gGmbHEssen, GermanyTaking people
- Klinikum Esslingen GmbHEsslingen am Neckar, GermanyTaking people
- Asklepios Klinik Gauting GmbHGauting, GermanyTaking people
- LungenClinic Grosshansdorf GmbHGrosshansdorf, GermanyTaking people
- Thoraxklinik Heidelberg gGmbHHeidelberg, GermanyTaking people
- Stiftung Krankenhaus Bethanien Fuer Die Grafschaft MoersMoers, GermanyTaking people
- Universitaetsklinikum Wuerzburg AöRWuerzburg, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- CatalYm GmbH
- Trial code
- NCT07246863EU 2024-516794-70-00
- Record updated
- 26 October 2026
- Original description
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor).Read full original descriptionShow less
Ph 2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab and Nivolumab With or Without Docetaxel Versus Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-02)
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti-GDF-15 antibody Visugromab (CTL-002) at two different dose levels plus Nivolumab with Docetaxel versus Visugromab at the higher dose plus Nivolumab with placebo versus double-placebo with Docetaxel, in participants that receive second-line treatment for non-squamous NSCLC after failure of prior first-line treatment including a CPI (checkpoint inhibitor).
The trial consists of 3 Parts: an open-label Safety Run-in part (Part A) followed by a subsequent randomized phase 2b part with 4 treatment arms. After the treatment of 15 participants with visugromab at the expansion dose, an interim safety and preliminary efficacy analysis will be conducted (Part B), followed by the treatment of the remaining participants (Part C).
Main Inclusion Criteria:; Participants must have histologically or cytologically confirmed diagnosis of stage IV non-squamous NSCLC; Participants must have demonstrated absence of actionable mutations (e.g. EGFR, ALK, among others) that suggest/require treatment with available targeted agent; Participants must have failed one line of prior systemic treatment for metastatic NSCLC containing an approved anti PD (L)1 checkpoint inhibitor (CPI). The minimum treatment duration on this regimen must have been 12 weeks exposure for the CPI with no documented progression in this period. Failure of the prior line of systemic treatment for metastatic NSCLC must have occurred under ongoing CPI treatment. Discontinuation of the prior CPI and line of treatment due to AEs, or any other reason than progression/relapse does not permit enrollment; Participants must have measurable disease determined by the local site Investigator by their assessment per RECIST v1.1; Participants must have life expectancy of at least 3 months as assessed by the Investigator; Participants must have ECOG performance status ≤1; Main Exclusion Criteria:; Participants must not have received more than one line of prior systemic treatment for advanced/metastatic NSCLC; Participants must not have a prior malignancy requiring treatment; Participants must not have a known or detected clinically active central nervous system (CNS) involvement by NSCLC or other tumors, e.g., with symptomatic metastases and/or carcinomatous meningitis; Participants must not have any active autoimmune disease that has required systemic treatment in past 3 months before planned treatment start (i.e., with use of disease modifying agents, corticosteroids, or immunosuppressive drugs); Participants must not have interstitial lung disease or a history of (non-infectious) pneumonitis that required systemic steroids or current pneumonitis.